about
Challenges in pulmonary hypertension: managing the unexpectedTreatment goals of pulmonary hypertensionBMPR2 mutations and survival in pulmonary arterial hypertension: an individual participant data meta-analysisManagement of pulmonary arterial hypertension associated with congenital systemic-to-pulmonary shunts and Eisenmenger's syndrome.Pulmonary arterial hypertension: from the kingdom of the near-dead to multiple clinical trial meta-analysesPulmonary arterial hypertension associated to connective tissue diseases.A meta-analysis of randomized controlled trials in pulmonary arterial hypertensionRare causes of pulmonary hypertension: spectrum of radiological findings and review of the literature.Pulmonary hypertension due to left heart disease: analysis of survival according to the haemodynamic classification of the 2015 ESC/ERS guidelines and insights for future changes.Tadalafil in idiopathic or heritable pulmonary arterial hypertension (PAH) compared to PAH associated with connective tissue disease.Left Main Coronary Artery Compression in Patients With Pulmonary Arterial Hypertension and Angina.Ambrisentan use for pulmonary arterial hypertension in a post-authorization drug registry: The VOLibris Tracking Study.Impact of Thrombolytic Therapy on the Long-Term Outcome of Intermediate-Risk Pulmonary Embolism.Combining bosentan and sildenafil in pulmonary arterial hypertension patients failing monotherapy: real-world insights.GPs Meet Rare Lung Disorders Task Force factsheet: pulmonary arterial hypertension.Current era survival of patients with pulmonary arterial hypertension associated with congenital heart disease: a comparison between clinical subgroups.Pulmonary hypertension and systemic sclerosis: the role of high-resolution computed tomography.Pulmonary artery intimal sarcoma. Problems in the differential diagnosis.Fibrinolysis for patients with intermediate-risk pulmonary embolism.Bronchial artery embolization for the treatment of haemoptysis in pulmonary hypertension.Pulmonary vascular disease due to left heart disease: how to achieve a more accurate approach beyond the haemodynamic phenotype: reply.Pulmonary hypertension and pulmonary arterial hypertension: a clarification is needed.A new CT-score as index of hemodynamic changes in patients with chronic thromboembolic pulmonary hypertension.Pulmonary veno-occlusive disease: the role of CT.Lung neovascularity in pulmonary arterial hypertension associated with congenital heart defects and idiopathic pulmonary arterial hypertension: study of 198 patients.The difficult diagnosis of pulmonary vascular disease in heart failure.Dissecting histone deacetylase role in pulmonary arterial smooth muscle cell proliferation and migration.Exercise training in pulmonary hypertension: improving performance but waiting for outcome[Female gender and pulmonary arterial hypertension: a complex relationship]Complications of Right Heart Catheterization Procedures in Patients With Pulmonary Hypertension in Experienced CentersReply: Left Main Extrinsic Compression in Pulmonary Arterial Hypertension: From Identification to Percutaneous Coronary Intervention Optimization
P50
Q26775848-B808E4C0-7308-420B-89BE-F14FFD9D9765Q26851767-C4BA4D19-C07E-4E24-BD19-4F31009E9CAAQ31038854-7620388F-96E2-4D73-9602-D95913D8D7A0Q33156291-DA14DA31-9E57-4AC3-AAFB-2F1D69EA1030Q34095714-D77ED23D-5BCF-407F-8A9E-32657B1C94D4Q36283465-474F7A97-E2A9-432D-A429-20B3E8F5F35FQ37097714-76E00702-82A9-426E-B47E-2F151C6348CBQ38162774-EB6E3761-4153-492B-BCEC-9559761363B2Q38688453-D6A873EA-BD56-465A-AFAA-CD5C4A03F4A1Q38916851-8D83772A-39E8-481C-BA61-BF28902235CCQ39154554-329511D4-3C15-4620-8220-0C859E795B13Q39695915-C4F9F7F6-D0EE-45A4-91F1-CF6B5702D8B7Q40277108-14B008C6-6C95-4340-B86E-6AFB820B40CAQ41709612-54312EB1-7BBA-4AE3-A7A1-78B8FDC2B8E3Q41998913-C6CE3594-EF48-4286-89D3-A822085A0425Q43481191-0DE52229-6E65-4AE6-9494-ED6F8EA007D4Q43754038-8E0B5E08-BE78-4BDD-B2FD-9F9F3A1E72B5Q44849846-33E18E4E-53A7-4ADB-B002-403F61CADD65Q45144900-85374CC9-409D-419A-9197-5698C8C1552BQ48116204-8FE53BE2-48D4-449D-AA94-DF1053755027Q50099133-FA40E522-1560-46EA-98DE-AA00089E6B9AQ51642225-AEB9EB61-1CC3-4E06-B24B-6A8095154E0AQ52948255-DC217D0A-4E9C-4922-AAB8-6BF2E911D361Q53086934-3A5CF434-25A1-473E-A98C-114EAED13462Q53183113-2E48C83E-72CC-45AA-A9B6-924F17E760D3Q53775598-195FB531-0FB8-422A-9A06-CB359D1AD90FQ54334954-97B3EDDE-2241-4CBA-8408-24F80E0855A9Q56966662-EE18CB25-FA75-4E40-BA44-F2E545B02EEAQ56981461-29D9CD97-5FAD-4504-91AE-F18DD4CE4AC6Q57824280-23028F45-51FE-4D6B-95A6-5DB7D82CFE9BQ89809628-18E71EF5-8023-4115-A450-D2E150CA5CD8
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Massimiliano Palazzini
@ast
Massimiliano Palazzini
@en
Massimiliano Palazzini
@es
Massimiliano Palazzini
@nl
type
label
Massimiliano Palazzini
@ast
Massimiliano Palazzini
@en
Massimiliano Palazzini
@es
Massimiliano Palazzini
@nl
prefLabel
Massimiliano Palazzini
@ast
Massimiliano Palazzini
@en
Massimiliano Palazzini
@es
Massimiliano Palazzini
@nl
P106
P1153
18037988400
P31
P496
0000-0002-6778-1994